Dong-A ST and Ipsen Korea Sign a Joint Sales Agreement for Deferelin...Synergy in precocious puberty and prostate cancer
Jun 30, 2025
|
Diperelin is a GnRH (Growth gland stimulation release hormone) agent developed by Ibsen and is a treatment for central precocious puberty and prostate cancer.
The two companies will jointly carry out Diperelin's domestic promotion and marketing activities from July 1. The two companies will cooperate together with the general hospital, and Dong-A ST will be in charge of the business for hospitals and clinics.
Dong-A ST, which has growth hormone drugs 'Grotropin' and urology treatments 'Zaidena' and 'Flivas', has abundant sales and marketing experience and expertise accumulated in pediatric endocrine and urology fields.
Ibsen Korea supplies a variety of anticancer drugs in Korea, including 'diperelin', advanced renal cell cancer, hepatocellular carcinoma, and differentiated thyroid cancer treatment 'carbometics', and acromegaly and neuroendocrine tumor treatment 'somatulin'. A new drug for advanced familial bile identification 'Bill Bay' will also be launched in Korea.
Based on their accumulated capabilities and expertise, the two companies plan to actively expand Diperelin's domestic market by creating synergy.
Jeong Jae-hoon, President of Dong-A ST, said "Cooperation with Ipsen Korea will be an important opportunity to expand the domestic supply of Diperelin and improve patient accessibility."We will combine the capabilities and expertise of both companies to provide more effective treatment options for domestic patients and create synergy in the field of precocious puberty and anticancer drugs."
This article was translated by Naver AI translator.
